

**STERLING BIOTECH LIMITED**  
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST DECEMBER, 2009**

(Rs.in Lacs)

Sr. No.	Particulars	3 months ended	Corresponding 3	For the Year	For the Year
		31/12/2009	months ended	Ended	Ended 31/12/2008
		Unaudited	Unaudited	Audited	Audited
1	Income				
	a) Net Sales/Income from Operations	36,841.18	33,073.20	143,817.29	117,838.07
	b) Other Operating Income	493.22	236.18	886.42	1,003.26
	<b>c) Total</b>	<b>37,334.40</b>	<b>33,309.38</b>	<b>144,703.71</b>	<b>118,841.33</b>
2	Expenditure				
	a) (Increase)/decrease in stock in trade and work in progress	(2,920.19)	848.26	(17,130.11)	313.09
	b) Consumption of raw materials	18,202.57	12,334.88	77,749.36	42,153.95
	c) Employees Cost	1,037.61	944.19	4,017.22	3,522.48
	d) Depreciation	3,034.76	2,881.30	12,304.21	10,715.18
	e) Other expenditure	7,268.65	6,292.13	28,629.32	21,718.36
	<b>f) Total</b>	<b>26,623.40</b>	<b>23,300.76</b>	<b>105,570.00</b>	<b>78,423.06</b>
3	Profit from Operations before Other Income and Interest (1-2)	10,711.00	10,008.62	39,133.71	40,418.27
4	Other Income	0.00	0.00	0.00	0.00
5	Profit before Interest (3+4)	10,711.00	10,008.62	39,133.71	40,418.27
6	Interest	5,150.00	2,442.31	14,943.77	5,920.71
7	<b>Profit (+) / Loss (-) from Ordinary Activities before tax (5-6)</b>	<b>5,561.00</b>	<b>7,566.31</b>	<b>24,189.94</b>	<b>34,497.56</b>
8	Tax expense				
	a) Current	815.00	750.00	3,500.00	3,750.00
	b) Deffered	1,125.00	1,850.00	3,350.00	7,550.00
	c) Fringe Benefit	0.00	12.50	12.50	47.50
	d) Total	1,940.00	2,612.50	6,862.50	11,347.50
9	<b>Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)</b>	<b>3,621.00</b>	<b>4,953.81</b>	<b>17,327.44</b>	<b>23,150.06</b>
10	Extraordinary Items	6,993.62	(283.16)	6,205.12	(1,132.64)
11	<b>Net Profit (+)/Loss (-) for the period (9-10)</b>	<b>10,614.62</b>	<b>4,670.65</b>	<b>23,532.56</b>	<b>22,017.42</b>
12	Prior year adjustment	166.97	(99.29)	166.97	(99.29)
13	<b>Profit available for appropriation</b>	<b>10,781.59</b>	<b>4,571.36</b>	<b>23,699.53</b>	<b>21,918.13</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,501.97	2,437.98	2,501.97	2,437.98
15	Reserves excluding Revaluation Reserves as per balance sheet.			204,530.55	170,359.64
16	Earnings Per Share (EPS)				
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.45	2.03	6.93	9.50
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	4.24	1.92	9.41	9.03
17	Public Shareholding				
	- Number of shares	133,666,531	127,267,548	133,666,531	127,267,548
	- Percentage of shareholding	53.42%	52.20%	53.42%	52.20%
18	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	Number of shares	30,527,000	32,488,136	30,527,000	32,488,136
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	34.29%	36.49%	34.29%	36.49%
	Percentage of shares (as a % of the total share capital of the Company)	12.20%	13.33%	12.20%	13.33%
	b) Non-encumbered				
	Number of shares	58,507,694	56,546,558	58,507,694	56,546,558
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	65.71%	63.51%	65.71%	63.51%
	Percentage of shares (as a % of the total share capital of the Company)	23.38%	23.19%	23.38%	23.19%

**STERLING BIOTECH LIMITED**  
**REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021**

**AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST DECEMBER, 2009**

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on March 31, 2010 and have been audited by the Statutory Auditors of the Company.
- 3 During the Quarter 1500 tons capacity of Gelatin was fully operationalised
- 4 The Board has recommended 50% Dividend (Rs. 0.50 per equity share of Re1/- each) subject to approval of members at the ensuing Annual General Meeting.
- 5 During the Quarter the Company has Repurchased / Bourght Back FCCBs due 2010 of face value of USD 7.5 Million, and FCCBs due 2012 of Face Value of USD 83.00 Million and as a result the outstanding amount of FCCBs are reduced to USD 93.67 Million and USD 134.50 Million respectively.
- 6 The number of investor complaints for the quarter ended on 31st December, 2009 were :  
Opening - NIL, Received - 13, Disposed off - 13, and Balance - NIL.
- 7 Previous period figures have been regrouped/reclassified, wherever necessary.

**For and on Behalf of**  
**STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : March 31, 2010

**Chetan J. Sandesara**  
**Joint Managing Director**